Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock - $0.001 par value
-
Shares outstanding
-
128M
-
Number of holders
-
99
-
Total 13F shares, excl. options
-
64M
-
Shares change
-
+1.91M
-
Total reported value, excl. options
-
$654M
-
Value change
-
+$18.3M
-
Put/Call ratio
-
0.05
-
Number of buys
-
59
-
Number of sells
-
-33
-
Price
-
$10.21
Significant Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) as of Q4 2022
113 filings reported holding CTKB - Cytek Biosciences, Inc. - Common Stock - $0.001 par value as of Q4 2022.
Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) has 99 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 64M shares
of 128M outstanding shares and own 50.04% of the company stock.
Largest 10 shareholders include RA CAPITAL MANAGEMENT, L.P. (13.4M shares), HHLR ADVISORS, LTD. (8.68M shares), BlackRock Inc. (8.37M shares), VANGUARD GROUP INC (7.77M shares), BROWN CAPITAL MANAGEMENT LLC (5.11M shares), STATE STREET CORP (2.04M shares), GEODE CAPITAL MANAGEMENT, LLC (1.79M shares), Blue Water Life Science Advisors, LP (1.3M shares), PERCEPTIVE ADVISORS LLC (1.29M shares), and Nuveen Asset Management, LLC (1.17M shares).
This table shows the top 99 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.